LL-37
Also known as: Cathelicidin, CAP18
Primary recreational use: Immune support and infection control
What is LL-37?
LL-37 is the only human cathelicidin antimicrobial peptide, derived from hCAP18, with significant antimicrobial and immune modulatory properties. It is used primarily for its wound healing and broad-spectrum antimicrobial activities, including action against antibiotic-resistant bacteria. While it shows promising results in clinical trials for chronic wound healing, it is not yet FDA-approved, and users should be cautious of potential toxicity and inflammatory side effects.
Primary Benefits
Broad-spectrum antimicrobial activity. Promotes wound healing. Reduces inflammation.
How It Works
LL-37 disrupts microbial cell membranes and modulates immune responses by promoting immune cell migration. Its cationic nature allows it to bind to bacterial membranes, forming pores that lead to cell death, while also engaging in immune signaling pathways to enhance wound healing and reduce inflammation.
Safety Tips
Precautions reported in community discussions and literature. This is not a complete list.
- 1.DON'T start with high doses; begin with the lowest effective dose.
- 2.DON'T use if you have a history of autoimmune conditions without medical advice.
- 3.DON'T apply or inject on unclean skin to avoid contamination.
- 4.DON'T exceed recommended durations to prevent toxicity.
- 5.NEVER use homemade formulations due to sterility risks.
- 6.DON'T use concurrently with substances causing hypersensitivity to peptides.
- 7.AVOID using LL-37 without medical supervision if pregnant or breastfeeding.
- 8.DON'T store above recommended temperatures to maintain stability.
- 9.DON'T mix LL-37 with non-sterile solutions.
Use Contexts
Different purposes have different protocols, dosing, and considerations
Chronic wound healing
moderate evidenceInvestigated for wound healing and antimicrobial activity against infections resistant to antibiotics. Used in clinical trials for chronic venous ulcers and skin conditions.
Evidence: Clinical trials have shown LL-37 accelerates wound healing and reduces bacterial presence on wound surfaces.
The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.
Timing: Morning
Notes: Dosage should be adjusted based on the severity of infection and wound state.
Community-Reported Protocols
Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.
| Reported Goal | Reported Dose | Reported Frequency | Reported Route |
|---|---|---|---|
| Wound healing | 0.5 mg/mL | twice weekly | Topical gel application |
Pharmacokinetics
Reported Side Effects
This is not a complete list. Other side effects may occur.
Common
Serious / Rare
- High-dose toxicity concerns
Injection-Specific Warnings
- Sterile technique is essential to avoid contamination.
Storage
Antimicrobial therapy
moderate evidenceUsed for its broad-spectrum activity against bacteria, viruses, and fungi in investigational research settings. Particularly considered as an alternative to conventional antibiotics.
Evidence: Research indicates LL-37 is effective against a wide range of pathogens and biofilm-related infections.
The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.
Timing: Morning
Notes: Adjust dose based on pathogen type and infection severity.
Community-Reported Protocols
Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.
| Reported Goal | Reported Dose | Reported Frequency | Reported Route |
|---|---|---|---|
| Microbial infection control | 100 mcg | once daily | Subcutaneous injection |
Pharmacokinetics
Reported Side Effects
This is not a complete list. Other side effects may occur.
Common
Serious / Rare
- Risk of developing autoimmune conditions
Injection-Specific Warnings
- Use caution with MCAS or histamine sensitivity.
Storage
Harm Reduction Information
Quality Concerns
- Contamination with non-sterile water
- Improper pH leading to irritation
Safety Tips
- Always use bacteriostatic water for reconstitution.
- Rotate injection sites to avoid skin damage.
- Avoid exceeding recommended dose ranges initially.
Warning Signs to Stop
- Severe allergic reactions
- Persistent inflammation or discomfort at site
- New or changed skin lesions
Seek Medical Help Immediately If
- Severe pain or extensive ulceration at application site
- Signs of systemic infection such as fever
Frequently Asked Questions
Common questions about LL-37
How long until I see effects?
LL-37 typically shows initial effects within the first 1-2 weeks, particularly in wound healing contexts.
What time of day should I take it?
LL-37 is best taken in the morning to support daytime immune surveillance.
How can I minimize side effects?
To minimize side effects of LL-37, ensure proper dosing and sterile application or injection techniques.
Does tolerance develop?
There is no substantial evidence of tolerance development with LL-37, but individual responses can vary.
How should I store it?
LL-37 should be stored refrigerated at 2-8°C and protected from light to maintain efficacy.
Do I need to cycle it?
While specific cycling protocols for LL-37 are not detailed, follow recommended durations and protocols for safe use.
Reported Combinations
Compounds reported to be used alongside LL-37 in community discussions
BPC-157
Enhanced wound healing and repair
TB-500
Complementary regenerative properties
Conventional Antibiotics
Increased antimicrobial efficacy
Vitamin D3
Supports immune function modulation
Lactoferrin
Combined immune boosting and antimicrobial effects
Reported Interactions
Interactions reported in literature and community discussions.
Synergistic antimicrobial effects but monitor for hypersensitivity.
Supports immune modulation; generally safe to combine.
Compatible with potential immune support benefits.
Potential for increased inflammation; monitor closely.
Avoid due to enhanced inflammatory response risk.
Reconstitution Calculator
100 units = 1 mL
Safety Tips
- Always consult a licensed medical professional for dosing and reconstitution instructions.
- Always double check your units. Mixing up mg and mcg can be very dangerous.
- Make sure to select your syringe type. U-100 and U-50 syringes have different units.
- Ensure you're not adding more BAC than your vial can hold. Most vials have maximum capacities listed.
This calculator is for informational and educational purposes only. It does not provide medical advice, dosing recommendations, or safety determinations. Reference ranges shown are compiled from publicly available sources and are not a substitute for guidance from a licensed healthcare professional.
Legal Status by Region
Regulatory status varies by country
USA
investigational
UK
investigational
EU
investigational
Australia
investigational
Canada
investigational
Explore More Research
Browse our database of peptide research information compiled from published literature and community sources.
Citations
Last updated: October 3, 2023